POSTMENOPAUSAL OSTEOPOROSIS
Clinical trials for POSTMENOPAUSAL OSTEOPOROSIS explained in plain language.
Never miss a new study
Get alerted when new POSTMENOPAUSAL OSTEOPOROSIS trials appear
Sign up with your email to follow new studies for POSTMENOPAUSAL OSTEOPOROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Bone-Building drug showdown: which works better for brittle bones?
Disease control OngoingThis study tests two FDA-approved medications for osteoporosis in 50 postmenopausal women at high risk of fractures. The goal is to see which drug improves hip bone density more over 12 months. Participants must not have used certain other osteoporosis treatments recently.
Matched conditions: POSTMENOPAUSAL OSTEOPOROSIS
Phase: PHASE4 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 15, 2026 19:05 UTC
-
Bone-Boosting combo could help women with osteoporosis
Disease control OngoingThis study looks at whether adding abaloparatide to the usual denosumab treatment can improve bone density more than denosumab alone in postmenopausal women with osteoporosis. About 70 women who have already had at least four denosumab shots will take part. The goal is to see if …
Matched conditions: POSTMENOPAUSAL OSTEOPOROSIS
Phase: PHASE4 • Sponsor: Hospital for Special Surgery, New York • Aim: Disease control
Last updated Jun 15, 2026 18:55 UTC
-
New bone drug LYN101 enters first human tests
Disease control ENROLLING_BY_INVITATIONThis early-stage study tests a new drug called LYN101 in healthy volunteers and postmenopausal women with low bone mass, who are at risk for fractures. The goal is to check the drug's safety and how the body processes it. About 44 participants will receive either the drug or a pl…
Matched conditions: POSTMENOPAUSAL OSTEOPOROSIS
Phase: PHASE1 • Sponsor: Shanghai TTM-Bio Technology Co., Ltd • Aim: Disease control
Last updated Jun 10, 2026 13:25 UTC
-
New bone drug shows promise for older women with weak bones
Disease control OngoingThis study tests an experimental drug called AGA2118 in women aged 55 to 80 who have low bone density after menopause. The goal is to see if the drug can increase bone strength in the spine and other areas over 12 months compared to a placebo. Participants must be generally healt…
Matched conditions: POSTMENOPAUSAL OSTEOPOROSIS
Phase: PHASE2 • Sponsor: Angitia Biopharmaceuticals • Aim: Disease control
Last updated Jun 09, 2026 12:07 UTC